Strata Critical Medical (SRTA) Cash from Investing Activities (2019 - 2026)

Strata Critical Medical (SRTA) has 7 years of Cash from Investing Activities data on file, last reported at $24.7 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 21.18% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.1 million (up 1532.45% YoY) and the FY2025 annual result came in at $69.8 million, up 6965.16% from the prior year.
• Cash from Investing Activities improved to $24.7 million in Q1 2026 per SRTA's latest filing, from $18.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $207.6 million in Q2 2022 and bottomed at -$16.9 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $11.0 million (2022), against an average of $21.9 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities jumped 20849.06%; it then tumbled 548.01% in 2024.
• Tracing SRTA's Cash from Investing Activities over 5 years: stood at $207.6 million in 2022, then sank by 99.96% to $75000.0 in 2023, then jumped by 5201.33% to $4.0 million in 2024, then soared by 359.38% to $18.3 million in 2025, then soared by 35.39% to $24.7 million in 2026.
• Per Business Quant, the three latest SRTA Cash from Investing Activities figures stand at $24.7 million (Q1 2026), $18.3 million (Q4 2025), and $2.4 million (Q3 2025).

Peer Comparison